Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study
- 1 May 2020
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (3), e13331
- https://doi.org/10.1111/dth.13331
Abstract
The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase. Evaluation of the effectiveness of oral propranolol is less established when it is administered in late infancy following the proliferative phase. We aimed to assess the clinical outcomes of pediatric patients managed by oral propranolol beyond the proliferative phase of IH. A retrospective cohort study in a tertiary health care referral center was conducted to track all patients with IH receiving systemic propranolol following the proliferative phase. Twenty-eight eligible patients were managed by 2 to 3 mg/kg per day of oral propranolol for IH beyond the proliferative phase, defined at 9 months of age. The mean age at the initiation of propranolol was estimated at 11.25 (SD 2.24) months. All eligible patients experienced some degree of clinical resolution, with the average improvement rate being estimated at 77.1% (SD 16.1). Comparable results were achieved among patients who were placed on propranolol at an age older than 12 months and those managed between the age of 9 and 12 months. No serious adverse events were observed during the follow-up duration. In conclusion, oral propranolol is a safe and effective treatment for patients with IH initiating this agent beyond the proliferative phase.This publication has 17 references indexed in Scilit:
- Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 CasesJournal of Oral and Maxillofacial Surgery, 2016
- Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation PhasePediatric Dermatology, 2015
- A Randomized, Controlled Trial of Oral Propranolol in Infantile HemangiomaThe New England Journal of Medicine, 2015
- Late Rebound of Infantile Hemangioma after Cessation of Oral PropranololPediatric Dermatology, 2013
- Infantile HemangiomaPlastic and Reconstructive Surgery, 2012
- Propranolol Induces Regression of Hemangioma Cells Through HIF-1α–Mediated Inhibition of VEGF-AAnnals of Surgery, 2012
- Untreated Hemangiomas: Growth Pattern and Residual LesionsPlastic and Reconstructive Surgery, 2011
- Oral Propranolol Therapy for Infantile Hemangiomas Beyond the Proliferation Phase: A Multicenter Retrospective StudyPediatric Dermatology, 2011
- Growth Characteristics of Infantile Hemangiomas: Implications for ManagementPEDIATRICS, 2008
- Propranolol for Severe Hemangiomas of InfancyThe New England Journal of Medicine, 2008